Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Turcot syndrome 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Bevacizumab 30pembrolizumab 29Oxaliplatin 28Leucovorin 25Fluorouracil 24Irinotecan 22Cetuximab 21Capecitabine 19Nivolumab 15Specimen Handling 12atezolizumab 11Panitumumab 10Colonoscopy 9Carboplatin 9regorafenib 8Biopsy 8trifluridine tipiracil drug combination 7Trifluridine 7Paclitaxel 7Aspirin 7balstilimab 6Standard of Care 6Cisplatin 6tislelizumab 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunoglobulin G 5Folfox protocol 5Disulfides 5trametinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Neoplasms × danvatirsen × Clear all
NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
39 enrolled
GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡